- The Company QMS
- Inspection gradings, including finding upgrades when cumulative
- CAPAs and approvals
- Risk analysis of findings
The reason for attending this talk is to understand where the Regulators will focus their attention when it comes to inspections involving pharmacovigilance activities from individual report production and reporting to signal detection; benefit-risk and risk minimization programs.
The focus will be on what processes are in place, training for individuals, database systems, etc… and this will involve Clinical; Regulatory; PV; IT; and QA Departments.
Serious Regulatory findings can cause clinical trials to be stopped/delayed; product suspensions; large Company fines and further Regulatory scrutiny.
Pharmacovigilance inspections are becoming increasingly more of a global occurrence. The sharing of such inspection reports between the various Regulators is again increasing, allowing Regulators to know if Sponsors of Clinical trials or license holders are in a compliant position regarding the safety of their products, which means that multiple inspections and findings can face those Companies that do not have robust internal audit programs and experienced auditors to keep them compliant.
“The future belongs to individuals and companies who embrace the entrepreneurial spirit, whether that is inside or...
A properly-composed JHA/AHA is one of the primary documents that large clients are increasingly asking to review in adva...
Skills-based hiring has been a topic of interest for many businesses and governments for the past few years. But even as...
Copyright © 2023 GRC Educators. All Rights Reserved